High-throughput screening and small animal models, where are we?

被引:214
作者
Giacomotto, Jean [1 ]
Segalat, Laurent [1 ]
机构
[1] Univ Lyon 1, CGMC, CNRS UMR5534, F-69622 Villeurbanne, France
关键词
Caenorhabditis elegans; Drosophila melanogaster; Danio rerio; high throughput screening; drug discovery; chemical genetics; disease; drug target; SMALL-MOLECULE SCREEN; CAENORHABDITIS-ELEGANS; C-ELEGANS; DROSOPHILA-MELANOGASTER; HUMAN-DISEASE; ZEBRAFISH MODEL; TARGET IDENTIFICATION; SYSTEMATIC ANALYSIS; AUTOMATED-ANALYSIS; DRUG DISCOVERY;
D O I
10.1111/j.1476-5381.2010.00725.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Current high-throughput screening methods for drug discovery rely on the existence of targets. Moreover, most of the hits generated during screenings turn out to be invalid after further testing in animal models. To by-pass these limitations, efforts are now being made to screen chemical libraries on whole animals. One of the most commonly used animal model in biology is the murine model Mus musculus. However, its cost limit its use in large-scale therapeutic screening. In contrast, the nematode Caenorhabditis elegans, the fruit fly Drosophila melanogaster, and the fish Danio rerio are gaining momentum as screening tools. These organisms combine genetic amenability, low cost and culture conditions that are compatible with large-scale screens. Their main advantage is to allow high-throughput screening in a whole-animal context. Moreover, their use is not dependent on the prior identification of a target and permits the selection of compounds with an improved safety profile. This review surveys the versatility of these animal models for drug discovery and discuss the options available at this day.
引用
收藏
页码:204 / 216
页数:13
相关论文
共 140 条
[1]   Zebrafish in functional genomics and aquatic biomedicine [J].
Aleström, P ;
Holter, JL ;
Nourizadeh-Lillabadi, R .
TRENDS IN BIOTECHNOLOGY, 2006, 24 (01) :15-21
[2]   Guide to receptors and channels (GRAC), 3rd edition [J].
Alexander, Stephen P. H. ;
Mathie, Alistair ;
Peters, John A. .
BRITISH JOURNAL OF PHARMACOLOGY, 2008, 153 :S1-S209
[3]   Reduced life span with heart and muscle dysfunction in Drosophila sarcoglycan mutants [J].
Allikian, Michael J. ;
Bhabha, Gira ;
Dospoy, Patrick ;
Heydemann, Ahlke ;
Ryder, Pearl ;
Earley, Judy U. ;
Wolf, Matthew J. ;
Rockman, Howard A. ;
McNally, Elizabeth M. .
HUMAN MOLECULAR GENETICS, 2007, 16 (23) :2933-2943
[4]   Insertional mutagenesis in zebrafish [J].
Amsterdam, A .
DEVELOPMENTAL DYNAMICS, 2003, 228 (03) :523-534
[5]  
Arias Alfonso Martinez, 2008, V420, P1, DOI 10.1007/978-1-59745-583-1_1
[6]  
Artal-Sanz Marto, 2006, Biotechnology Journal, V1, P1405, DOI 10.1002/biot.200600176
[7]   Genome-wide RNAi analysis of Caenorhabditis elegans fat regulatory genes [J].
Ashrafi, K ;
Chang, FY ;
Watts, JL ;
Fraser, AG ;
Kamath, RS ;
Ahringer, J ;
Ruvkun, G .
NATURE, 2003, 421 (6920) :268-272
[8]   Integration of virtual and high-throughput screening [J].
Bajorath, F .
NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (11) :882-894
[9]   Zebrafish: an emerging technology for in vivo pharmacological assessment to identify potential safety liabilities in early drug discovery [J].
Barros, T. P. ;
Alderton, W. K. ;
Reynolds, H. M. ;
Roach, A. G. ;
Berghmans, S. .
BRITISH JOURNAL OF PHARMACOLOGY, 2008, 154 (07) :1400-1413
[10]   The NemaGENETAG initiative: large scale transposon insertion gene-tagging in Caenorhabditis elegans [J].
Bazopoulou, Daphne ;
Tavernarakis, Nektarios .
GENETICA, 2009, 137 (01) :39-46